AI Meets Biotech — and Hedge Funds Are Buying In
Caris Life Sciences’ IPO is backed by some of the industry’s biggest names as it pitches itself as a “next-gen TechBio” player.
Recent Articles
Opinion: Can the ‘Alpha in the Elevators’ Give Active Managers the Edge They Need?
Companies that have strong relationships with their employees outperform their peers. And it’s quantifiable — and investable.
“Deficit Hawks? Try Chicken Hawks,” Says JPMorgan’s Michael Cembalest
House Republicans’ budget adds trillions in debt — and shreds their fiscal credibility, with Medicaid cuts and other trims failing to offset the cost.
Michelle Celarier
June 4, 2025
